Aytu BioPharma (AYTU) Stock Price, News & Analysis

Company Overview

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

Key Stats

• Today's Range: $1.50 to $1.63
• 50-Day Range: $1.49 to $2.85
• 52-Week Range: $1.41 to $3.45
• Volume: 27,366 shs
• Average Volume: 22,704 shs
• Market Capitalization: $10.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aytu BioPharma Stock Analysis - MarketRank™

Aytu BioPharma scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aytu BioPharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aytu BioPharma is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aytu BioPharma is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aytu BioPharma has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.24% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Aytu BioPharma has recently decreased by 14.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aytu BioPharma does not currently pay a dividend.

Dividend Growth

Aytu BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.45

Percentage of Shares Shorted

3.24% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Aytu BioPharma has recently decreased by 14.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.50

News Sentiment

Aytu BioPharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aytu BioPharma this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for AYTU on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.77% of the stock of Aytu BioPharma is held by insiders.

Percentage Held by Institutions

Only 33.49% of the stock of Aytu BioPharma is held by institutions.

AYTU Stock Analysis - Frequently Asked Questions

How have AYTU shares performed this year?

Aytu BioPharma's stock was trading at $2.84 at the start of the year. Since then, AYTU shares have decreased by 42.6% and is now trading at $1.63.
View the best growth stocks for 2024 here.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) announced its quarterly earnings data on Thursday, September, 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.37. The business earned $17.98 million during the quarter. Aytu BioPharma had a negative net margin of 8.28% and a negative trailing twelve-month return on equity of 21.89%.

When did Aytu BioPharma's stock split?

Aytu BioPharma's stock reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's top institutional investors include Stonepine Capital Management LLC (8.15%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka.
View institutional ownership trends.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), General Electric (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

• Last Earnings: 9/26/2024
• Today: 11/22/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AYTU
• CUSIP: N/A
• CIK: 1385818
• Web: aytubio.com
• Phone: (720) 437-6580
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,840,000.00
• Net Margins: -8.28%
• Pretax Margin: -6.76%
• Return on Equity: -21.89%
• Return on Assets: -5.37%

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 0.99
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $79.76 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.85 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 6,149,000
• Free Float: 5,979,000
• Market Cap: $10.02 million
• Optionable: Not Optionable
• Beta: -1.40